Recovery & Repair · Recovery & Repair peptide (research)
IGF-1 DES
- Drug class
- Recovery & Repair peptide (research)
- Status
- Compounded (503A)
- Also known as
- igf1 des, des(1-3) igf-1, igf-1 des(1-3), des igf
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What IGF-1 DES is studied for
- Localized tissue repair (research)
- Satellite cell activation (research)
- Lower systemic IGF-1 exposure (research)
Mechanism of action
IGF-1 DES is being studied in the recovery & repair category. Truncated IGF-1 variant studied for localized muscle and tissue repair. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is IGF-1 DES?
IGF-1 DES is a recovery & repair peptide. Truncated IGF-1 variant studied for localized muscle and tissue repair.
What is IGF-1 DES studied for?
Published research has examined IGF-1 DES for localized tissue repair, satellite cell activation, lower systemic igf-1 exposure. Human clinical evidence varies by indication.
Is IGF-1 DES FDA-approved?
No. IGF-1 DES is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is IGF-1 DES used in research?
Protocols vary by study. IGF-1 DES is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for IGF-1 DES is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.